

Special Issue

10th Anniversary of Biomedicines—Advances in New Pharmacological Therapies

Message from the Guest Editor

Drugs are bioactive compounds that were originally discovered in the chemical structures that are present in both the plant and animal kingdoms. Both organic and inorganic compounds have been used empirically to cure diseases or to treat the symptoms that are derived from them. Much of modern pharmacology has its origins in these types of compounds. Due to advancements in chemistry, we are able to characterize the chemical composition of any compound with a high degree of accuracy. In fact, we are continuing to discover new compounds in nature that demonstrate very promising pharmacological activities, which could lay the foundation for new, more efficient, and more effective bioactive molecules through chemical modifications. Furthermore, pharmacology is advancing, as new synthetic compounds with increasingly specific and effective pharmacological properties are being developed at a rapid pace. Therefore, in this Special Issue, we plan to collect the latest advances in new drugs of either natural or synthetic origin in addition to describing their biological targets, their specific mechanisms of action, and their effective dosages.

Guest Editor

Dr. Juan Gambini

Freshage Research Group, Department of Physiology, Faculty of Medicine, University of Valencia, E46010 Valencia, Spain

Deadline for manuscript submissions

closed (15 November 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/106318

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).